FDA’s warning letters about these drugs

The shape of the page

Six searches, run against FDA’s own index. It reads the whole text of every letter rather than a drug field, so a letter appears here if it mentions the word anywhere.

The page is recent. FDA issued 62 of the semaglutide letters in 2026 alone, and the years before that are much thinner. This is a young enforcement picture rather than a settled one.

Why every count here is a floor

FDA’s index searches the words in a letter. A letter that misspells the drug is therefore invisible to a drug search, including FDA’s own.

The letter to FormPour is the example. The letter spells the drug class GLT-1 rather than GLP-1. FDA’s own index returns nothing for GLT-1, so no drug search on this site or anyone else’s finds this letter. We found it by company name and it is in the table below. There is no way to know how many others are hiding the same way.

That letter, and every search that misses it is set out term by term on its own page. Many sites selling these drugs are not registered with FDA at all, so nothing they do produces a letter.

Letters get closed out

A company answers a letter, FDA reviews what it did, and FDA can publish a close-out letter saying the matter is resolved. Of the 150 letters below, 2 carry one. Each is marked in its own row with the date.

An empty close-out column is not the opposite. A close-out letter is something a company has to ask FDA for, and plenty of resolved matters never get one. The column shows what FDA has published and nothing more.